Tidal Investments LLC Sells 24,386 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Tidal Investments LLC lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 42.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 33,541 shares of the biopharmaceutical company’s stock after selling 24,386 shares during the period. Tidal Investments LLC’s holdings in Alnylam Pharmaceuticals were worth $10,097,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $25,000. HM Payson & Co. bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. Finally, Manchester Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Sanford C. Bernstein restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Jefferies Financial Group increased their target price on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research note on Tuesday. Chardan Capital reissued a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Barclays decreased their target price on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. Finally, Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $376.67.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $248.68 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The company has a fifty day moving average of $254.43 and a 200 day moving average of $288.99. The stock has a market capitalization of $33.28 billion, a price-to-earnings ratio of 46.22 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.51) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).